{
    "clinical_study": {
        "@rank": "48664", 
        "arm_group": {
            "arm_group_label": "cross-over", 
            "arm_group_type": "Experimental", 
            "description": "Four periods separated by a wash out lasting up to 3 days at maximum. At each period, application of one product (twice). Duration of treatment period: From 4 to 13 days."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the clinical efficacy, the safety and acceptability\n      of three new oral sprays with a reference oral spray in the relief of drug-induced\n      xerostomia associated with hyposialia, i.e. dryness of the mouth induced by a decrease of\n      salivation (hyposialia) induced by chronic drug intake."
        }, 
        "brief_title": "Exploratory Study in the Relief of Drug-induced Xerostomia Associated With Hyposialia", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Drug-induced Xerostomia", 
        "condition_browse": {
            "mesh_term": "Xerostomia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects,\n\n          -  Adult subjects (\u226518 years) taking drug(s) causing salivary hypofunction / xerostomia,\n             for at least 1 week prior to study initiation and expected to continue without change\n             during study\n\n          -  Subjects with a complaint of dry mouth as assessed by a response of 40mm or greater\n             on item \"Rate the dryness of your mouth\" of the Dry Mouth Visual Analogue Scale (VAS)\n             questions. (The VAS limits will be 0 representing normal [i.e. no dry mouth symptoms]\n             and 100 representing \"the worst imaginable\" dry mouth symptoms). This score should\n             also be met before the 1st product application, on P1 D1.\n\n          -  Documented hyposalivation with test of resting saliva weight absorbed \u2264 0.5g/5 min at\n             baseline\n\n        Exclusion Criteria:\n\n          -  Presence of disorders (bucco-dental disease, history of major medical/psychiatric\n             illness or surgery, ... ) which, in the judgement of the investigator, may interfere\n             with study implementation and/or study parameter assessment(s).\n\n          -  Sj\u00f6gren syndrome and related autoimmune diseases,\n\n          -  Other medical causes of xerostomia (oral candidiasis).\n\n          -  History of head and neck irradiation and cancer chemotherapy\n\n          -  History of hypersensitivity to any of the components of the investigational products,\n\n          -  History or current excessive use of alcohol,\n\n          -  History of drug addiction,\n\n          -  Presence of treatments for their dry mouth within 7 days prior to inclusion into the\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005328", 
            "org_study_id": "DC0161 BS 0 01", 
            "secondary_id": "CIV-13-10-011648"
        }, 
        "intervention": [
            {
                "arm_group_label": "cross-over", 
                "description": "Application of  product in the mouth twice daily", 
                "intervention_name": "Tested product : DC161-DP0291", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "cross-over", 
                "description": "Application of  product in the mouth twice daily", 
                "intervention_name": "Tested product : DC161-DP0292", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "cross-over", 
                "description": "Application of  product in the mouth twice daily", 
                "intervention_name": "Tested product : DC161-DP0293", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "cross-over", 
                "description": "Application of product in the mouth twice daily", 
                "intervention_name": "Reference product: solution for oromucosal sprays", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Xerostomia", 
            "hyposialia", 
            "hyposalivation", 
            "saliva substitute", 
            "Salivary Gland", 
            "Mouth Diseases", 
            "Dry mouth"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Erfurt", 
                    "country": "Germany"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study of the Effect and Safety of Three New Oral Sprays and a Reference Marketed Oral Spray in the Relief of Drug-induced Xerostomia Associated With Hyposialia.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Germany: Ethics Commission"
            ]
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Dry mouth will be self-rated using item \"Rate the dryness of your mouth\" of the Dry Mouth Visual Analogue Scale questions.", 
            "measure": "Observed area under the curve of dry mouth evaluations", 
            "safety_issue": "No", 
            "time_frame": "11 points : from baseline (before application) and up to 4 hours after the first product application"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005328"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pierre Fabre Medicament", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pierre Fabre Medicament", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}